Baidu
map

可能改变癌症治疗的新方法:液体活检

2015-05-13 佚名 生物谷

在美国,一种新的血液检测方法正开始改变癌症治疗,为一些病人省去了手术活检和穿刺活检,这两种活检是长期需要来指导病人癌症治疗的。 这种被称为液体活检的检测方法,可以捕获到肿瘤脱落进入血液的肿瘤细胞或DNA,从而替代了从肿瘤本身提取组织。关于这些检测方法的价值,现在还有很多不清楚的地方,但是许多医生认为,这些检测方法是一个很大的进步,可能可以为更多的病人实现个体化治疗。 这些检测方法是第一

在美国,一种新的血液检测方法正开始改变癌症治疗,为一些病人省去了手术活检和穿刺活检,这两种活检是长期需要来指导病人癌症治疗的。

这种被称为液体活检的检测方法,可以捕获到肿瘤脱落进入血液的肿瘤细胞或DNA,从而替代了从肿瘤本身提取组织。关于这些检测方法的价值,现在还有很多不清楚的地方,但是许多医生认为,这些检测方法是一个很大的进步,可能可以为更多的病人实现个体化治疗。

这些检测方法是第一次非介入性地,可重复性地抽取肿瘤样本,医生们从而可以建立基因表达谱,靶向突变用药,快速判断治疗是否有效,及随肿瘤的发展而调节治疗方案。

两年前,这些检测方法除了在科研中,此外很少用到。现在, 有几种已经在出售,十几种正在开发中,还有一些,医生们已经用到了常规治疗中。

Gurpaul Bedi的大肠癌有一个肺部的转移。目前在德州大学MD安德森癌症中心,约10%的有转移性大肠癌的患者正在接受液体活检。

"我觉得这种方法很棒,"Bedi说,他住在亚特兰大,来到休斯顿接受治疗。"很多医生告诉我,要做肺部活检,很不容易。"

在费城,液体活检比常规的检查提前了几个月,查出了Carole Linderman的乳腺癌复发。

"如果没有这种检查方法,我们可能直到有症状时,才会知道在我的脊柱上有癌症了,"她说,那样的话,再接受好的治疗就太晚了。

这些液体检测方式有巨大的潜力。问题是:目前仍没有大量的,权威性的研究来表明,这些方法可以帮助患者,它们有多精确,哪种方法是最好的,谁应该使用它们及什么时候使用。

而且,当药物对患者的肿瘤很对症的时候,患者病情才会好转,所以,更加频繁地使用液体检测,可能会是一种很实用的方式。

"我对此感到很兴奋,"加州大学圣迭戈分校癌症专家Razelle Kurzrock博士说,"我一生中有很多时候,给患者用了没有效果的药物,因为没有一种好的方法告诉我,哪些药物将对患者有效,或者是可以快速判断哪些药物对患者无效。现在情况就好多了。"她说。

原始出处:

By Marilynn Marchione.New blood tests, liquid biopsies, may transform cancer care.MedicalXpress, May 11, 2015.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1844168, encodeId=c4dc1844168e7, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Apr 20 14:07:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903090, encodeId=e0ba1903090b5, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Apr 17 21:07:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33427, encodeId=2eea3342ee4, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a25c1635554, createdName=byzh1990, createdTime=Sat Jul 25 03:01:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24569, encodeId=8e8424569f7, content=牛逼!, beContent=null, objectType=article, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160515/IMG57380B859AD1F1019.jpg, createdBy=2c5c1621956, createdName=jasonuclear, createdTime=Fri May 22 23:24:00 CST 2015, time=2015-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277953, encodeId=5fd012e7953ed, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri May 15 00:07:00 CST 2015, time=2015-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23335, encodeId=084d2333553, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 13 20:20:00 CST 2015, time=2015-05-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1844168, encodeId=c4dc1844168e7, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Apr 20 14:07:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903090, encodeId=e0ba1903090b5, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Apr 17 21:07:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33427, encodeId=2eea3342ee4, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a25c1635554, createdName=byzh1990, createdTime=Sat Jul 25 03:01:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24569, encodeId=8e8424569f7, content=牛逼!, beContent=null, objectType=article, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160515/IMG57380B859AD1F1019.jpg, createdBy=2c5c1621956, createdName=jasonuclear, createdTime=Fri May 22 23:24:00 CST 2015, time=2015-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277953, encodeId=5fd012e7953ed, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri May 15 00:07:00 CST 2015, time=2015-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23335, encodeId=084d2333553, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 13 20:20:00 CST 2015, time=2015-05-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1844168, encodeId=c4dc1844168e7, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Apr 20 14:07:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903090, encodeId=e0ba1903090b5, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Apr 17 21:07:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33427, encodeId=2eea3342ee4, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a25c1635554, createdName=byzh1990, createdTime=Sat Jul 25 03:01:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24569, encodeId=8e8424569f7, content=牛逼!, beContent=null, objectType=article, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160515/IMG57380B859AD1F1019.jpg, createdBy=2c5c1621956, createdName=jasonuclear, createdTime=Fri May 22 23:24:00 CST 2015, time=2015-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277953, encodeId=5fd012e7953ed, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri May 15 00:07:00 CST 2015, time=2015-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23335, encodeId=084d2333553, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 13 20:20:00 CST 2015, time=2015-05-13, status=1, ipAttribution=)]
    2015-07-25 byzh1990

    期待

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1844168, encodeId=c4dc1844168e7, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Apr 20 14:07:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903090, encodeId=e0ba1903090b5, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Apr 17 21:07:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33427, encodeId=2eea3342ee4, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a25c1635554, createdName=byzh1990, createdTime=Sat Jul 25 03:01:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24569, encodeId=8e8424569f7, content=牛逼!, beContent=null, objectType=article, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160515/IMG57380B859AD1F1019.jpg, createdBy=2c5c1621956, createdName=jasonuclear, createdTime=Fri May 22 23:24:00 CST 2015, time=2015-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277953, encodeId=5fd012e7953ed, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri May 15 00:07:00 CST 2015, time=2015-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23335, encodeId=084d2333553, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 13 20:20:00 CST 2015, time=2015-05-13, status=1, ipAttribution=)]
    2015-05-22 jasonuclear

    牛逼!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1844168, encodeId=c4dc1844168e7, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Apr 20 14:07:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903090, encodeId=e0ba1903090b5, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Apr 17 21:07:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33427, encodeId=2eea3342ee4, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a25c1635554, createdName=byzh1990, createdTime=Sat Jul 25 03:01:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24569, encodeId=8e8424569f7, content=牛逼!, beContent=null, objectType=article, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160515/IMG57380B859AD1F1019.jpg, createdBy=2c5c1621956, createdName=jasonuclear, createdTime=Fri May 22 23:24:00 CST 2015, time=2015-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277953, encodeId=5fd012e7953ed, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri May 15 00:07:00 CST 2015, time=2015-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23335, encodeId=084d2333553, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 13 20:20:00 CST 2015, time=2015-05-13, status=1, ipAttribution=)]
    2015-05-15 smlt2008
  6. [GetPortalCommentsPageByObjectIdResponse(id=1844168, encodeId=c4dc1844168e7, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Apr 20 14:07:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903090, encodeId=e0ba1903090b5, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Apr 17 21:07:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33427, encodeId=2eea3342ee4, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a25c1635554, createdName=byzh1990, createdTime=Sat Jul 25 03:01:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24569, encodeId=8e8424569f7, content=牛逼!, beContent=null, objectType=article, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160515/IMG57380B859AD1F1019.jpg, createdBy=2c5c1621956, createdName=jasonuclear, createdTime=Fri May 22 23:24:00 CST 2015, time=2015-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277953, encodeId=5fd012e7953ed, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri May 15 00:07:00 CST 2015, time=2015-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23335, encodeId=084d2333553, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 13 20:20:00 CST 2015, time=2015-05-13, status=1, ipAttribution=)]
    2015-05-13 huaxipanxing

    看看

    0

相关资讯

Nature Commu: 惊!房间温度居然影响癌症治疗效果?

近日,来自美国纽约Roswell Park癌症中心免疫系的Hylander研究组发现,房间温度引起的应激可以通过对β2-肾上腺素受体的激活,来抑制癌症治疗的效果,相关结果发表于3月10号的《Nature Communication》杂志上。 研究人员用患有严重胰腺癌的小鼠作为肿瘤研究模型,实验小鼠分别饲养在适宜温度30°C和标准温度22°C条件下。 首先,研究人员发现,在适宜温度30°C条件下,

癌症治疗取得新进展—“A45肿瘤治疗”技术在京发布

近日,由大基医疗集团(TG)精心研发、独家生产的高技术医疗设备DJ-A45医用电子加速器,获得美国食品药品监督管理局(FDA)和我国国家食品药品监督管理总局(CFDA)注册。美国FCCC肿瘤中心和美国费城肿瘤医院无锡分院,利用大基医疗独家生产的DJ-A45电子加速器和闪烁分层摄影仪(简称DS)高科技设备,利用分子影像诊断和皮摩尔脏器功能测定等填补国际空白技术,经过多年联合临床研究和实践,形成了全球

Nature系列综述:利用复制应激治疗癌症的现状与展望

近日,丹麦科学家Claus Storgaard S?rensen在国际学术期刊nature reviews drug discovery发表了一篇综述文章,对利用癌细胞DNA复制应激进行癌症治疗的相关研究进展进行了总结讨论和展望。   癌细胞的DNA复制一般会伴随着复制叉的拖延和崩溃,以及应答DNA损伤和未成熟有丝分裂的信号通路激活,这些过程统称为"复制应激"。目前有许多研究对复

美国医学会诊意见—癌症患者的理想的指南

对于你的癌症治疗,获得一个第二医学意见有6个好处:  1.感觉到有能力实现和控制局势—通过积极主动的寻求第二医学意见,你和你爱的人将会更加熟悉所有可能的治疗选择。你将获得更多关于你所患癌症和治疗选择方面的信息,能够帮助你感到能够掌握你的健康情况。  2.自信和平静的心态—一份第二医学意见能帮助你感到更多的自信,你能搞选择正确的治疗计划。根据一项研究,1/8的癌症患者被误诊。有些时候,一个第二医学意

Cancer Lett:萤火虫点亮癌症治疗未来

近日,刊登在国际杂志Cancer Letters上的一篇研究论文中,来自Norris Cotton癌症研究中心的研究人员通过研究表示,使得萤火虫发光的机制,即生物发光的机制或可用于研究肿瘤对疗法的反应。文章中研究者Gimi表示,利用携带多发性肿瘤的动物模型进行研究,我们建立了一个新型的平台,其可以在需要较少动物模型的基础上高效地进行肿瘤研究实验;而多发性肿瘤动物模型的另一个益处就是其可以在对研究结

Nature:Ras蛋白研究复兴,寻找癌症治疗新靶标

经过30年的追寻,科学家试图发明可以治疗致命致癌蛋白家族——Ras蛋白——的药物研究失败了。现在,他们希望通过另外一种全新的方法实现这一目标。 当Stephen Fesik离开制药行业并筹建理论药物发现实验室时,他草拟了一份“通缉单”:上面列着迄今为止科学上已知的5种最重要的致癌蛋白。这些蛋白可以促进肿瘤生长,但是对于药物研发人员来说:它们却因为太光滑、太懒惰或是太烦琐,而难以与药物

Baidu
map
Baidu
map
Baidu
map